BiotechTubeBiotechTube
Home/United Therapeutics/James Edgemond
JE

James Edgemond

Chief Financial Officer

United Therapeutics

Therapeutic Areas

Pulmonary Arterial HypertensionRare DiseasesPulmonary HypertensionGene TherapyXenotransplantation

United Therapeutics Pipeline

DrugIndicationPhase
Treprostinil (Remodulin)Pulmonary Arterial HypertensionCommercial
Treprostinil (Tyvaso)PAH and PH-ILDCommercial
Treprostinil (Orenitram)Pulmonary Arterial HypertensionCommercial
Selexipag (Uptravi)Pulmonary Arterial HypertensionCommercial
RalinepagPulmonary Arterial HypertensionPhase 3
Aurora-GTAADC DeficiencyPhase 1/2
Xenotransplant ProgramOrgan TransplantationPre-clinical
RemUnity PumpPAH Drug DeliveryDevelopment

Leadership Team at United Therapeutics

DM
Dr. Martine Rothblatt
Chairman and Chief Executive Officer
MB
Michael Benkowitz
President and Chief Operating Officer
DL
Dr. Leigh Peterson
Chief Medical Officer
DD
Dr. David Nagle
Chief Technology Officer
PM
Paul McCudden
Chief Commercial Officer
DC
Dr. Christopher Paige
Executive Vice President, Research and Development
View full United Therapeutics profile